Osiris Therapeutics (OSIR) researches, develops, manufactures, markets, and distributes regenerative medicine products.
OSIR products include Grafix, a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns; BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery; and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects.
Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
December 5, 2019
RegMed Investors’ (RMi) closing bell: the sector is what it is until it isn’t and even then it doesn’t seem to be
December 4, 2019
RegMed Investors’ (RMi) closing bell: volume is picking up in a positive close
December 3, 2019
RegMed Investors’ (RMi) closing bell: sector rolls as Audentes Therapeutics’ (BOLD) acquisition stimulates interest in gene therapy
December 2, 2019
RegMed Investors’ (RMi) closing bell: right again as the sector dives
November 29, 2019
RegMed Investors’ (RMi) closing bell: an early and positive sector close
November 27, 2019
RegMed Investors’ (RMi) closing bell: the sector notched its fourth straight day of gains
November 26, 2019
RegMed Investors’ (RMi) closing bell: volume shapes the upside
November 25, 2019
RegMed Investors’ (RMi) closing bell: up, up and away
November 22, 2019
RegMed Investors’ (RMi) closing bell: a messy week ends on a positive note
35 companies, 1 interpreter!
Insight, foresight and recommendation
Osiris Therapeutics (OSIR) – Late Filing, SEC issues, officer crimminal indictments and yet another COO departs (number 5 in four years?). Started the year 2018 at $6.15, dived and jived to $6.95 by 2/1 and achieved $9.08 by 2/21. Once their "clean" it will be worth a near term topic until then "play" monopoly with the shares ... NO trust
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors